Why Is Pharvaris Stock Surging Today?

Pharvaris NV saw its shares climb 12.4% during morning trading after the company announced statistically significant and clinically meaningful topline results from its CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for the prevention of hereditary angioedema (HAE) attacks. The global, double-blind, placebo-controlled trial, which enrolled 85 adolescents and adults across 21 countries, met its primary endpoint by reducing the mean monthly HAE attack rate by 83% versus placebo, with a p-value below 0.0001. All secondary efficacy endpoints also achieved statistical significance, and the treatment demonstrated a well-tolerated safety profile.

These results hold particular significance because CHAPTER-3 is the first and only Phase 3 prophylaxis study to have evaluated all three HAE types, with patients suffering from HAE Type 1 or Type 2 showing an even stronger 87% reduction in attacks versus placebo. Pharvaris confirmed that it will use these findings as the basis for regulatory filings, including a U.S. New Drug Application planned for the first half of 2027. The company's existing analyst coverage—which includes Overweight ratings from Morgan Stanley and Wells Fargo, along with Buy ratings from Guggenheim, RBC Capital, and Oppenheimer—had already priced in substantial expectations ahead of the readout, and the strength of the data validated that bullish consensus.

The broader market gave little support on the day, as the S&P 500 slipped 0.4% and the Nasdaq also declined 0.4%, underscoring that PHVS's rally was driven entirely by its own clinical news flow rather than any macroeconomic or sectorwide catalyst. The shares reached a session high of $43.25, a fresh 52-week peak, before easing back to trade around $39.61.

Overall, the combination of a clean primary endpoint, robust secondary data across all HAE subtypes, and a well-defined regulatory path gave investors reason to sharply reprice the stock. On a cumulative basis, the shares have more than doubled from their 52-week low of $20.65, illustrating how transformative a successful late-stage readout can be for a clinical-stage biopharmaceutical company.

This article was produced with AI assistance and reviewed by an editor. For more details, see our Terms & Conditions.